July #103 : Women('s) Count(s) - by Rebecca Minnich

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Lost In Paradise

Kiss & Tell

Our Infectors, Ourselves

Velvet Gloves

A Pathway to Peace

His Diff'rent World

Earthwatch

Fear Factor

African Idols

Tribute: Keith Cylar

Burning Rubber

War of the Worlds

Oprah on the DL

C No Evil?

When Nature Calls

Briefs

Liver It Up

Inner Guinea Pig

Cancer Rising

Quick Study: Dementia

Senior Class

Women('s) Count(s)

Fit to Print

The Acting Bug

Editor's Letter

Mailbox

The Art of Healing



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

July 2004

Women('s) Count(s)

by Rebecca Minnich

Results from long-term studies of women with HIV have been hitting the news, and some of the news is good. Those who start HAART amid advanced-stage HIV, or AIDS, can still snag good results, says the Women’s Interagency HIV Study (WIHS). The March report may encourage those who still think that folks launching HAART with CD4 counts below 200 won’t benefit.

The six-year study of 1,132 women HIVers focused on HAART virgins with CD4s below 200 and viral loads over 10,000. Almost half had previously suffered at least one opportunistic infection.

“The results were greater than we expected,” says principal investigator Kathryn Anastos, MD, of Montefiore Medical Center in the Bronx, New York. Eighty percent of the women pumped up their CD4s to 200 or more; within five years, 55 percent had surpassed 350. The upshot: In long-term treatment it’s the on-HAART, not pre-HAART, figure that counts.

Twenty percent of the women didn’t respond well to therapy—their CD4s stayed below 200. The reason remains a mystery, but the researchers point to poor adherence, drug resistance, active drug use and depression as common factors.

But the main theme is encouraging: “As long as the CD4 comes up above 200,” Anastos says, “the woman is protected, no matter where she started. It’s never too late to begin HAART.” She adds that the message applies to men as well.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    Poz_Qt
    Columbus
    Ohio


    TaintedloveDC
    Washington
    DC


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.